Therefore, this trial aim to evaluate the efficacy of carvedilol-SR on the outcome [N-terminal pro-B-natriuretic peptide (NT-proBNP) concentration] in patients with hypertension and HFpEF, and will assess the differential effects of these drugs on the outcome, according to GLS categories. The gene discussed is NPPB; the disease is hypertensive disorder.